Almirall, S.A (ALM) Fair Value & Analysis
Healthcare · ES · Market cap €2.3B
Fair value as of: Jul 20, 2026
From 25 valuation models · updated yesterday
Fair value updated Jul 20, 2026, revised from €4.74 to €4.67 (−1.5%) since Jul 14, 2026. Share price −1.6% over the past month.
Price vs Fair Value (12 months)
12‑month range €10.01 – €13.64 · fair‑value band €3.50 – €5.84 · the €10.94 price screens above the €4.67 fair value. As of Jul 20, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Almirall, S.A (ALM) currently trades at €10.94, while our model-based Fair Value estimate is €4.67, implying the stock looks roughly 57.3% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Almirall, S.A generated revenue of €1.1B at a net margin of 3.6%. Revenue grew 2.2% year over year. It earns a return on equity of 2.7%. Net debt stands at €5.1M. Fundamentals as of Jul 20, 2026
Our scenario range runs from €3.50 (bear case) to €5.84 (bull case); at €10.94, the current price sits above that range. The share trades about 21% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -57%, ALM screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 20, 2026. TTM = trailing twelve months.
About the company
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Almirall, S.A reported revenue of €1.1B in FY2025 versus €827M in FY2021, a compound +7.6%/yr. Reported net income was €46.2M in FY2025.
Is ALM fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,247 | ₹2,697 | +20% |
| Mankind Pharma Limited MANKIND | ₹2,336 | ₹1,068 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Almirall, S.A (ALM) undervalued?
What is the fair value of ALM?
What is the quality score of ALM?
What is the revenue of Almirall, S.A (ALM)?
What is the net profit margin of ALM?
Does Almirall, S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Almirall, S.A analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.